

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 to 7. (canceled)

Claim 8. (currently amended) A method of treating a disease of a posterior segment of an eye comprising administering subconjunctivally to a patient an effective amount for treatment of an injection comprising fine particles containing a drug and enabling the concentration of the drug in a retina-choroid to be sustained, the disease of the posterior segment of the eye being uvetis, cytomegalovirus retinitis, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy or retinal detachment, the fine particles containing the drug being a matrix-type, wherein the drug is dispersed uniformly in the fine particles, **[[and]]** a particle diameter of the fine particles being 50 nm to 150 μ m and the fine particles being made of a biodegradable polymer or a biosoluble polymer.

Claims 9 to 11. (canceled)

Claim 12. (previously presented) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the drug is betamethasone, dexamethasone, triamcinolone or prednisolone.

Claims 13 to 18. (canceled)

Claim 19. (previously presented) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a polylactic acid having a weight-average molecular weight of 20,000, and the drug is betamethasone.